CALL - SPRINTER OPEN END - GENMAB | Delayed Börse Stuttgart 02:40:24 2024-06-27 EDT | ||
| 9.48 EUR | +8.47% |
|
| Current month | -15.56% | ||
| 1 month | -24.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 9.48 | +8.47% |
| 24-06-26 | 8.74 | +4.55% |
| 24-06-25 | 8.36 | -8.53% |
| 24-06-24 | 9.14 | +12.29% |
| 24-06-20 | 8.14 | -6.76% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 02:40 am
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VA91YF |
| ISIN | DE000VA91YF9 |
| Date issued | 2018-11-21 |
| Strike | 1,140 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.72 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 30.62 € |
|---|---|
| Lowest since issue | 0.51 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,791
DKK
Average target price
2,464
DKK
Spread / Average Target
+37.58%
- Stock Market
- Certificates
- Certificat
